Brentuximab vedotin
Orphan Drug Cold Chain RequiredFDA Approved
Description
Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma. The ADC is composed of an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE).
Indications & Therapeutic Use
CD30+ cutaneous T-cell lymphoma
Global Availability (6 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Brentuximab vedotin
| Generic Name | Brentuximab vedotin |
| Brands | 1 brand available |
| Active Ingredient | Brentuximab vedotin |
| Drug Class | CD30+ cutaneous T-cell lymphoma |
| Manufacturer | Takeda Pharmaceutical Company |
| Dosage Forms | Intravenous injection |
| Medical Code | L01FX05 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT01109025 |
| Countries | 6 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations7 Validated Nodes